Pharmacology Research Institute

What Pharmacology Research Institute does

M3 Wake Research, operating under the legal name Pharmacology Research Institute, is a wholly owned subsidiary of M3 and operates an integrated network of premier investigational clinical trial sites across North America. The organization conducts clinical research studies evaluating the efficacy and safety of new investigational medications, therapies, medical devices, and disease management approaches for pharmaceutical, biotechnology, medical device, and clinical research organization (CRO) sponsors. Its study portfolio spans 14 therapeutic areas including Alzheimer's, autoimmune disorders, cardiology, dermatology, gastroenterology, hepatology/nephrology, neurology/behavioral health, obesity, oncology/hematology, orthopedics, pulmonology, diabetes, vaccines/prevention, and women's health.

The business is built around three operational pillars: participant recruitment (via a self-service website clinical trial finder, a community physician referral network, and an email-based participant referral program), trial conduct at equipped investigational sites with advanced diagnostic equipment, and standardized data collection and reporting to sponsors while preserving participant privacy. The company reports 674 studies completed and 19,000+ participants enrolled over the past five years, alongside 30+ years of clinical research experience. There is no public disclosure of revenue, funding rounds, leadership personnel, patents, or AI/ML capabilities in the source data.

Revenue mechanics follow a professional services model: sponsors and CROs pay for clinical trial conduct services, while participation is free for individual volunteers who may receive compensation for time and travel. Go-to-market combines B2B direct enterprise sales to pharmaceutical, biotech, medical device, and CRO buyers with B2C direct-to-consumer recruitment. The company is privately held under M3, a strategic operating parent, with operations based in Los Alamitos, California and a workforce of 51–100 employees.

Name

Pharmacology Research Institute

Legal name

M3 Wake Research

Website

https://priresearch.com

Company type

Private

Founded year

1994

Operating status

Operating

Headcount range

51–100 employees

Short description

M3 Wake Research (Pharmacology Research Institute) is a wholly owned M3 subsidiary operating an integrated North American network of clinical trial sites that recruit participants and conduct studies across 14 therapeutic areas for pharmaceutical, biotechnology, medical device, and CRO sponsors.

Ownership category

akta.pro rank

Product category

Clinical Research Services

NAICS

Research and Development in the Physical, Engineering, and Life Sciences (54171), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Health Services (8000)

akta.pro primary industry

Clinical Trial Site Operations & Study Coordination (HLAGACAE)

akta.pro secondary industry

Patient Recruitment, Site Feasibility & Trial Enablement CROs (HLAGAAAI)

Keywords

• Clinical research services
• Clinical trial conduct
• Investigational site network
• Patient recruitment services
• Therapeutic area trials

Headquarters

HQ city

Los Alamitos

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

1. Clinical Trial Services: Revenue generated by conducting clinical trials for pharmaceutical sponsors, biotechnology companies, medical device companies, and clinical research organizations. Services include participant recruitment, trial conduct, and data collection/analysis.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Core offering

Pharmacology Research Institute, operating as M3 Wake Research, conducts clinical research trials for biopharmaceutical, biotechnology, medical device, and pharmaceutical industry clients, as well as CROs. Services encompass participant recruitment, protocol-driven trial conduct at wholly owned investigational sites across North America, and collection/verification of medical data and results reporting. The company also recruits and enrolls individual volunteers through its website and community physician partnerships.

Product overview

M3 Wake Research is a unified clinical research platform offering integrated investigational site services to the biopharmaceutical, biotechnology, medical device, and pharmaceutical industries. The organization operates premier investigational sites across North America, providing a comprehensive portfolio of therapeutic area clinical studies including Alzheimer's, autoimmune disorders, cardiology, dermatology, gastroenterology, hepatology/nephrology, neurology/behavioral health, obesity, oncology/hematology, orthopedics, pulmonology, diabetes, vaccines/prevention, and women's health. Their core service encompasses participant recruitment, trial conduct, and results analysis, with a track record of 19K+ participants and 674 studies completed over 30+ years.

Differentiator

Problem solved

Functional benefit

Products and services

• Clinical Research Trial Services Core clinical research trial services for pharmaceutical, biotechnology, medical device, and CRO clients, evaluating the efficacy and safety of new investigational treatments, therapies, medical devices, and disease management approaches across a network of wholly owned investigational sites in North America.

Quantifiable outcome

• 19K+ participants enrolled in clinical studies over five years
• +2 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Four partnerships are on record, tiered core.

• Community PhysicianscoreStrategic or Co-development PartnerPartnership with community physicians for patient referrals to clinical trials. Physicians refer eligible patients while M3 Wake Research provides trial infrastructure and care.
• Biopharmaceutical CompaniescoreStrategic or Co-development PartnerCollaborative relationships with pharmaceutical companies to conduct clinical trials for new investigational medications, providing participant recruitment, trial conduct, and data collection services.
• Clinical Research Organizations (CROs)coreStrategic or Co-development PartnerSite network partnership with CROs for conducting multi-location clinical trials, providing standardized protocol execution and data collection across investigational sites.
• Medical Device CompaniescoreStrategic or Co-development PartnerPartnership with medical device companies to evaluate safety and efficacy of medical devices through clinical trials at equipped facilities.

Scale indicators4 records

Recent moves5 records

Expansion highlights4 records

Broad incumbents

• Medpace: Mid-to-large global CRO with strong site network partnerships and full-service clinical development. Competes for the same biopharma/biotech study awards as Wake Research.
• IQVIA: Largest global CRO that also operates site management services alongside full-service clinical trial delivery. Comparable end-customer base (biopharma/biotech sponsors) and overlapping SMO capability, but as part of a much broader portfolio.
• ICON plc: Large global CRO with dedicated site solutions (e.g., PRA Health, Symphony Clinical Research). Overlaps with Wake Research on site-based trial conduct and same biopharma sponsor customer base.
• Syneos Health: Biopharmaceutical services organization offering both CRO and site management capabilities, serving the same pharmaceutical/biotech sponsor base as Wake Research.

Direct peers

• Flourish Research: Multi-therapeutic-area integrated site network focused on Phase II–IV clinical trials for pharma and biotech sponsors. Comparable owned-site, multi-TA SMO operating model to Wake Research.
• Velocity Clinical Research: Integrated, wholly-owned multi-site clinical research organization in the U.S. operating a large network of investigational sites across multiple therapeutic areas — directly comparable business model and service offering to M3 Wake Research.
• Accelerated Enrollment Solutions (PPD/Thermo Fisher): Dedicated SMO subsidiary of a large CRO, operating a network of owned patient enrollment centers across the U.S. — same SMO business model as Wake Research but with parent CRO distribution leverage.
• Clinilabs: Clinical research site organization with multiple owned U.S. sites specializing in CNS, psychiatry, and other therapeutic areas — comparable site-based trial delivery to Wake Research.
• Altasciences (formerly WCCT Global): Multi-site early-phase clinical research organization offering site-based trial conduct across therapeutic areas. Closely comparable owned-site, multi-TA service model.

Emerging players

• Benchworks (Benchmark Research): Smaller multi-therapeutic-area site research organization providing Phase II–IV clinical trial conduct — partial overlap with Wake Research on owned-site trial delivery at sub-scale.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xtwitter.com/M3WakeResearch
• Facebookfacebook.com/WakeResearchAssociates
• LinkedInlinkedin.com/company/pharmacology-research-institute

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pharmacology Research Institute